ANCA-Associated Vasculitis: An Update

被引:78
|
作者
Almaani, Salem [1 ]
Fussner, Lynn A. [2 ]
Brodsky, Sergey [3 ]
Meara, Alexa S. [4 ]
Jayne, David [5 ]
机构
[1] Ohio State Univ, Div Nephrol, Wexner Med Ctr, Columbus, OH 43201 USA
[2] Ohio State Univ, Div Pulm & Crit Care Med, Wexner Med Ctr, Columbus, OH 43201 USA
[3] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43201 USA
[4] Ohio State Univ, Div Rheumatol, Wexner Med Ctr, Columbus, OH 43201 USA
[5] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England
关键词
ANCA vasculitis; review; vasculitis; crescentic glomerulonephritis; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; DAILY ORAL CYCLOPHOSPHAMIDE; CHURG-STRAUSS-SYNDROME; WEGENERS-GRANULOMATOSIS; MICROSCOPIC POLYANGIITIS; PLASMA-EXCHANGE; MAINTENANCE THERAPY; RANDOMIZED-TRIAL; RISK-FACTORS; REMISSION-MAINTENANCE;
D O I
10.3390/jcm10071446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The two major antigens targeted by ANCAs are leukocyte proteinase 3 (PR3) and myeloperoxidase (MPO). AAV can be classified into 3 categories based on patterns of clinical involvement: namely, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA). Clinically, AAV involves many organ systems including the lungs, kidneys, skin, and nervous system. The prognosis of AAV has improved dramatically due to advances in the understanding of its pathogenesis and treatment modalities. This review will highlight some of the recent updates in our understanding of the pathogenesis, clinical manifestations, and treatment options in patients with AAV focusing on kidney involvement.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] ANCA-Associated Renal Vasculitis - An Update
    Tesar, Vladimir
    Hruskova, Zdenka
    [J]. NEW INSIGHTS INTO GLOMERULONEPHRITIS: PATHOGENESIS AND TREATMENT, 2013, 181 : 216 - 228
  • [2] Pathogenesis of ANCA-Associated Vasculitis, an Update
    Cees G. M. Kallenberg
    [J]. Clinical Reviews in Allergy & Immunology, 2011, 41 : 224 - 231
  • [3] Pathogenesis of ANCA-associated vasculitis: An update
    Jarrot, Pierre-Andre
    Kaplanski, Gilles
    [J]. AUTOIMMUNITY REVIEWS, 2016, 15 (07) : 704 - 713
  • [4] Pathogenesis of ANCA-Associated Vasculitis, an Update
    Kallenberg, Cees G. M.
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2011, 41 (02) : 224 - 231
  • [5] Update on treatment of ANCA-associated vasculitis
    Holle, Julia U.
    Moosig, Frank
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024,
  • [6] Update on the Treatment of ANCA-associated Vasculitis
    Holle, Julia U.
    Moosig, Frank
    [J]. AKTUELLE RHEUMATOLOGIE, 2019, 44 (04) : 276 - 283
  • [7] An update on the epidemiology of ANCA-associated vasculitis
    Mohammad, Aladdin J.
    [J]. RHEUMATOLOGY, 2020, 59 : 42 - 50
  • [8] Avacopan for the treatment of ANCA-associated vasculitis: an update
    Osman, Mohammed
    Tervaert, Jan Willem Cohen
    Pagnoux, Christian
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (05) : 461 - 471
  • [9] Update on targeted treatments for ANCA-associated vasculitis
    Puechal, Xavier
    [J]. JOINT BONE SPINE, 2025, 92 (01)
  • [10] Update on Maintenance Therapies for ANCA-Associated Vasculitis
    Pagnoux, Christian
    Fifi-Mah, Aurore
    [J]. CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2021, 7 (02) : 112 - 133